Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Eli Lilly now expects 2024 revenue of $42.4 billion to $43.6 billion, up from its previous forecast of $40.4 billion to $41.6 billion. The drugmaker also raised its annual profit forecast by $1.30 ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
If you'd invested $10,000 in Eli Lilly stock five years ago, you would have $65,900 today. That's a gain worthy of a top growth player. Lilly managed to draw the attention of a wide range of investors ...
Eli Lilly shares were marked6.6% lower in early Thursday afternoon trading following the earnings release to change hands at $319.51 each, erasing all of the stock's six-month gains.
Eli Lilly and Company LLY posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. The pharmaceutical giant raised its outlook for 2024 on rapidly climbing ...
By Dean Seal Eli Lilly reports that more than half of Crohn's disease patients achieved clinical remission after a year of treatment with mirikizumab in ...
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Eli Lilly raised both ends of its 2024 revenue forecast by $2 billion and now expects $42.4 billion to $43.6 billion for the year. The drugmaker also raised its annual profit forecast by $1.30 per ...